To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects
ConditionSolid Tumor, Adult
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-45
SponsorJemincare
About this trial
Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers
Eligibility criteria
Qualifiers
Healthy, adult, male or female 18-45 years of age, inclusive.
Body mass index (BMI) between 19 and 28 kg/m2 (inclusive) and weight at least 50 kg.
Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
Disqualifiers
Patients with a history of clinically significant diseases including, but not limited to, gastrointestinal, renal, liver, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric, or cardiovascular and cerebrovascular diseases, epilepsy, bipolar disorder/mania, intraocular hypertension, or acute angle-closure glaucoma.
Female subjects with a positive pregnancy test or lactating.
Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or Treponema pallidum（TP-Ab）
Trial design
Treatments tested in this trial
- JMKX001899
- JMKX001899
- JMKX001899
- Placebo
Treatment groups
27 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov